Biogen unveils first spinal muscular atrophy data from Spinraza follow-onnews2025-06-25T11:30:34+00:00June 25th, 2025|Endpoints News|
Nektar reports positive Phase 2b rezpeg data in eczema, stock skyrocketsnews2025-06-24T15:12:26+00:00June 24th, 2025|Endpoints News|
UK government blueprints ambition to be a key life sciences hub news2025-06-24T11:17:28+00:00June 24th, 2025|Endpoints News|
Nuvalent closes in on FDA filing for lung cancer drug with topline Phase 1/2 datanews2025-06-24T11:14:18+00:00June 24th, 2025|Endpoints News|
Amgen plans more gradual MariTide dosing in Phase 3 news2025-06-23T20:25:37+00:00June 23rd, 2025|Endpoints News|
Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3news2025-06-23T19:33:19+00:00June 23rd, 2025|Endpoints News|
Exelixis’ positive Phase 3 colorectal cancer data boost stocknews2025-06-23T15:27:00+00:00June 23rd, 2025|Endpoints News|
Cidara’s preventive influenza biologic is effective in Phase 2b trialnews2025-06-23T14:38:50+00:00June 23rd, 2025|Endpoints News|
#ADA25: Lilly’s bimagrumab boosts weight and fat loss when added to Novo’s Wegovynews2025-06-23T13:00:57+00:00June 23rd, 2025|Endpoints News|
Compass reports Phase 3 depression data for psilocybin drugnews2025-06-23T10:30:59+00:00June 23rd, 2025|Endpoints News|
